Vera Therapeutics TRUTAKNA Shows Two-Year Kidney Benefit
Brisbane, California, USA, September 15, 2026 Vera Therapeutics has announced final efficacy results from the Phase 3 ORIGIN 3...
proteinuria
Advertisement
Alebund’s AP308 Gets FDA IND Clearance for IgA Nephropathy
Shanghai, China, September 8, 2026 Alebund Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has cleared...
Otsuka Advances VOYXACT with Landmark Two-Year Phase 3 IgAN Results
TOKYO, Japan, August 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced new two-year...
Novartis Fabhalta Wins Full FDA Approval for IgAN
BASEL, July 17, 2026 Novartis announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval for...
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
Advertisements
AstraZeneca’s Ultomiris Shows Strong IgAN Phase III Results
GLASGOW, Scotland – June 6, 2026 AstraZeneca’s rare disease division, Alexion, has reported positive interim Phase III results for...
Otsuka’s VOYXACT Preserves Kidney Function in Phase 3 IgAN Trial
GLASGOW, Scotland, June 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. have announced positive...
Travere Therapeutics Wins FDA Approval for FILSPARI in FSGS
San Diego, California | April 13, 2026 Travere Therapeutics, Inc. has announced that the U.S. Food and Drug Administration...
Novartis Fabhalta® Slows Kidney Function Decline in Phase III IgAN Study
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
Advertisement
